During Friday’s Current trade, Shares of Lexington Realty Trust (NYSE:LXP), lost -1.23% to $8.03.
Lexington Realty Trust (LXP) declared that it declared a regular common share/unit dividend/distribution for the quarter ending September 30, 2015 of $0.17 per common share/unit payable on or about October 15, 2015 to common shareholders/unitholders of record as of September 30, 2015.
Lexington also declared that it declared a cash dividend of $0.8125 per share of Series C Cumulative Convertible Preferred Stock for the quarter ending December 31, 2015. This Series C Preferred Share dividend is payable on or about February 16, 2016, to shareholders of record of Series C Preferred Shares as of January 29, 2016.
Lexington Corporate Properties Trust operates as a self-managed and self-administered real estate investment trust (REIT). The company acquires, owns, and manages a portfolio of office, industrial, and retail properties net-leased to corporate tenants in the United States.
Shares of Mirna Therapeutics Inc (NASDAQ:MIRN), declined -2.84% to $6.85, during its current trading session.
Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, declared the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $7.00 per share. The shares are predictable to start trading on The NASDAQ Global Market under the ticker symbol “MIRN” on October 1, 2015. In addition, Mirna has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price to cover over-allotments, if any. The offering is predictable to close on October 6, 2015 subject to customary closing conditions.
Citigroup and Leerink Partners are acting as joint book-running managers for the projected offering. Oppenheimer & Co. and Cantor Fitzgerald & Co. are acting as co-managers.
Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops microRNA-based oncology therapeutics. Its lead product candidate is MRX34, a mimic of naturally occurring microRNA-34 encapsulated in a liposomal nanoparticle formulation that is in Phase 1 clinical trial.
Enbridge Inc (USA) (NYSE:ENB), during its Friday’s current trading session increased 0.83% to $37.63.
Enbridge Inc. (ENB) declared it has closed the transfer of its Canadian Liquids Pipeline Business and certain Canadian renewable energy assets to Enbridge Income Fund (the “Fund”) for consideration of $30.4 billion plus additional incentive rights, as set out in the terms of a contract declared June 19, 2015.
The Transaction is a key component of Enbridge’s Financial Strategy Optimization introduced in December of last year, which comprised of an enhance to the Company’s targeted dividend payout. It advances the Company’s sponsored vehicle strategy and supports Enbridge’s formerly declared 33 percent dividend enhance in 2015 and predictable annual average dividend per share growth of 14 to 16 percent from 2016 through 2018. The Transaction is predictable to provide Enbridge with an alternate source of funding for its $44-billion enterprise-wide growth capital program and enhance its competitiveness in the pursuit of new organic growth opportunities and asset acquisitions.
Enbridge Inc. operates as an energy transportation and distribution company in the United States and Canada. Its Liquids Pipelines segment operates common carrier and contract crude oil, natural gas liquids (NGL), and refined products pipelines and terminals.
Finally, Quest Diagnostics (NYSE:DGX), decreased -0.89%, to $61.03.
Quest Diagnostics (DGX), the world’s leading provider of diagnostic information services, and Inovalon (INOV), a leading technology company providing advanced, cloud-based data analytics and data-driven intervention platforms to the healthcare industry, declared the national launch of Data Diagnostics™, a suite of hundreds of real-time patient-specific data analyses that clinicians can order individually, on demand at the point of care within their existing workflow to identify and address gaps in quality, risk, utilization and medical history insights. Unseen in healthcare recently, the solution supports the healthcare industry’s transition from volume- to value-based healthcare by providing actionable insight to improve clinical and quality outcomes in addition to financial performance for practices, health plans, ACOs, hospitals and other providers across the healthcare community in real time.
The solution draws on two of the world’s largest datasets of clinical, claims, quality and laboratory data, counting Quest’s 20 billion clinical laboratory test results and Inovalon’s clinical datasets on more than 123 million patients. Data Diagnostics™ is also unique for providing seamless integration within Quest’s Care360® and EHR lab ordering and connectivity platform serving about half of the physicians and hospitals in the United States. This integration means physicians can readily order and access Data Diagnostics™ reports within their existing clinical workflow, a functionality that is key to bringing the power of big data to the point of care in real time.
Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, in addition to related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; laboratory outreach services; and risk assessment services for the life insurance industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
